“Late this year, we expect to see the first data from our triple-acting incretin Retatrutide which combines GLP-1, GIP and glucagon.”

In context

“al submission for this indication in 2026. The Orforglipron Phase III trials in people with obesity, ATTAIN-1 and ATTAIN-2 are expected to read out in Q3 of this year. These trials will form the basis of our first Orforglipron regulatory submissions, which will be for the treatment of obesity, and we expect to occur late in 2025. This year, we also expect data from the tirzepatide cardiovascular outcome study SURPASS-CVOT. Of course, this is an event-based trial, and the time line is dependent on the accrual of cardiovascular events. We anticipate data in Q3. While designed to measure both non-inferiority and superiority compared to Trulicity, a positive outcome in either would demonstrate that tirzepatide reduces the risk of cardiovascular outcomes and would support a labeled indication. Late this year, we expect to see the first data from our triple-acting incretin Retatrutide which combines GLP-1, GIP and glucagon. We believe this potential new medicine can deliver even more weight loss than tirzepatide and could potentially provide additional health benefits. The initial study to read out TRIUMPH-4 is a 68-week study in patients with osteoarthritis of the knee who have a body mass index of 27 or greater. We'll also see multiple additional Jaypirca data sets this year. Physician feedback is very positive on experience with Jaypirca in the currently approved indications, and we hope that generating data in earlier lines of therapy will enable broader use within CLL and MCL. We could see data from additional trials in the first-line or BTK-naive settings this year. Moving to neurodegeneration. While we don't have a key event listed in 2025 for donanemab, we're closely watching the preclinical Alzheime”